替格瑞洛联合阿托伐他汀治疗急性冠状动脉综合征临床研究

目的探讨替格瑞洛联合阿托伐他汀治疗急性冠状动脉综合征的临床疗效,以及对患者血清脑钠肽(BNP)和血清肌钙蛋白Ⅰ(cTnⅠ)水平的影响。方法选取医院2015年8月至2017年8月收治的急性冠状动脉综合征患者120例,按随机数字表法分为观察组和对照组,各60例。两组患者均予阿司匹林肠溶片及注射用依诺肝素钠基础治疗,并予阿托伐他汀钙片,观察组患者加用替格瑞洛片。结果观察组总有效率为91.67%,显著高于对照组的76.67%(P<0.05)。与治疗前比较,两组患者治疗后的左室射血分数(LVEF)和BNP水平均显著升高,左室收缩末期内径(LVESd)、左室舒张末期内径(LVEDd)和cTnⅠ水平均显著降低,且观察组患者上述指标改善程度均显著优于对照组(P<0.05)。观察组与对照组不良反应发生率相当(13.33%比8.33%,χ~2=0.776,P=0.378>0.05)。观察组心血管不良事件发生率为5.00%,显著低于对照组的16.67%(P<0.05)。结论替格瑞洛联合阿托伐他汀治疗急性冠状动脉综合征疗效较好,能改善心功能指标,降低血清BNP和cTnⅠ水平。

Ticagrelor Combined with Atorvastatin in Patients with Acute Coronary Syndrome

Objective To study the clinical efficacy of ticagrelor combined with atorvastatin on acute coronary syndrome and its effect on serum brain natriuretic peptide(BNP)and cardiac troponinⅠ(cTnⅠ)levels.Methods A total of 120 patients with acute coronary syndrome treated in the hospital from August 2015 to August 2017 were selected and divided into the observation group and the control group according to random number table method,60 cases in each group.Both groups were treated with aspirin enteric-coated tablets and enoxaparin for injection and atorvastatin calcium tablets;the observation group were added with ticagrelor tablets.Results The total effective rate was 91.67%in the observation group,which was significantly higher than 76.67%in the control group(P<0.05).Compared with before treatment,the left ventricular ejection fraction(LVEF)and the levels of BNP in the two groups significantly increased,while the left ventricular end systolic diameter(LVESd),the left ventricular end diastolic diameter(LVEDd),and cTnⅠlevels in the two groups significantly decreased,and the improvements in the observation group were significantly better than those in the control group(P<0.05).The incidence of adverse reactions was 13.33%in the observation group and 8.33%in the control group,with no significant difference between the two groups(χ~2=0.776,P=0.378>0.05).The incidence of adverse reactions and cardiovascular adverse events(MACE)was 5.00%in the observation group,which was significantly lower than 16.67%in the control group(P<0.05).Conclusion Ticagrelor combined with atorvastatin has good efficacy in the treatment of acute coronary syndrome.It can improve the cardiac function of patients,reduce the levels of serum BNP and cTnⅠ.